Oramed Pharmaceuticals (ORMP) Long-Term Debt Issuances (2023 - 2025)

Oramed Pharmaceuticals' Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $65.5 million for Q2 2025.

• Quarterly Long-Term Debt Issuances rose 114.33% year-over-year to $65.5 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $134.7 million (up 171.8% YoY) and the FY2025 annual result came in at $69.2 million, up 39.66% from the prior year.
• Long-Term Debt Issuances was $65.5 million for Q2 2025 at Oramed Pharmaceuticals, down from $69.2 million in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $74.6 million in Q4 2023 and bottomed at $19.0 million in Q1 2024.
• A 3-year average of $51.8 million and a median of $65.5 million in 2025 frame the typical range for Long-Term Debt Issuances.
• Peak annual rise in Long-Term Debt Issuances reached 264.21% in 2025, while the deepest fall reached 114.33% in 2025.
• Oramed Pharmaceuticals' Long-Term Debt Issuances stood at $74.6 million in 2023, then sank by 59.02% to $30.6 million in 2024, then jumped by 114.33% to $65.5 million in 2025.
• Business Quant data shows ORMP's Long-Term Debt Issuances at $65.5 million in Q2 2025, $69.2 million in Q1 2025, and $30.6 million in Q2 2024.